HMNC Brain Health is a clinical-stage neuroscience company pioneering new therapies for mental health disorders. Its pipeline includes Nelivabon (BH-200), a vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders, and Ketabon (KET01), an oral prolonged-release ketamine formulation for treatment-resistant depression designed for outpatient and at-home use.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $50 M | Jun, 2026 | series-b |
Industries
Frequently Asked Questions
Where is HMNC Brain Health located?
HMNC Brain Health is located in Munich, Germany.
What industries does HMNC Brain Health operate in?
HMNC Brain Health operates in the following industries: biopharma, neuroscience, mental health, precision psychiatry.
How much total funding has HMNC Brain Health raised?
HMNC Brain Health has raised a total of $50,000,000.
Who are the investors in HMNC Brain Health?
The investors in HMNC Brain Health are: MEDICE – The Health Family, The Maschmeyer Group.
What is the primary focus of HMNC Brain Health?
HMNC Brain Health is a clinical-stage biopharmaceutical company that specializes in precision psychiatry. It focuses on developing personalized treatments for mental health disorders, specifically targeting Major Depressive Disorder (MDD) and treatment-resistant depression (TRD).
Is HMNC Brain Health a publicly traded company?
No, HMNC Brain Health is a private, venture-backed company and is not traded on any public stock exchange.
How does HMNC Brain Health integrate companion diagnostics into its treatments?
HMNC Brain Health uses an AI-powered platform to develop proprietary genetic companion diagnostics. These tests allow for patient stratification, identifying individuals who are most likely to respond to specific therapeutic compounds, thereby reducing trial-and-error prescribing.
What are the main development programs currently being pursued by HMNC Brain Health?
The company's core development portfolio includes Ketabon, an oral prolonged-release ketamine formulation for treatment-resistant depression, and Nelivabon, a biomarker-guided vasopressin V1b receptor antagonist for stress-related depressive disorders. Additionally, it has worked on the Cortibon program.
What is the mission of HMNC Brain Health?
The mission of HMNC Brain Health is to improve the lives of patients suffering from mental health disorders by pioneering precision psychiatry. By leveraging genomics, AI, and analytics, the company aims to move away from non-specific treatment models toward targeted, personalized therapies that offer higher remission rates and fewer side effects.